DSM-Firmenich stock outlook rises after volume-led Q3 growth

DSM-Firmenich raised its full-year sales outlook after a volume-led third quarter, according to the company's November 4 trading update. The Swiss-Dutch nutrition, health and beauty group lifted its 2026 like-for-like sales growth target to around 5%, from a previous range of 2% to 4%.

Continuing operations generated third-quarter sales of 2.368 billion euros, compared with 2.238 billion euros a year earlier. Like-for-like growth was 5%, consistent with the year-to-date trend, and management said volume was the main driver. High win rates on customer briefs and solid performance across regional and local accounts supported the result.

Margin progress supports the outlook

Adjusted EBITDA increased 8% on a like-for-like basis to 482 million euros, while the quarterly adjusted EBITDA margin reached 20.4%. The company said the margin included an 80-basis-point negative foreign-exchange effect against the prior-year quarter. Cost savings, restructuring measures and pricing actions are intended to offset cost inflation.

Chief Executive Dimitri de Vreeze said business conditions entering the fourth quarter remained supportive, citing a healthy innovation pipeline, high win rates and continued sales growth. He also said the 2026-2028 action plan was on track and that the group remained focused on cash and capital discipline.

For the full year, dsm-firmenich continues to target an adjusted EBITDA margin of around 20% and cash conversion of 11% to 12%, measured as adjusted gross operating free cash flow to sales. The higher sales target therefore improves the top-line outlook without changing the profitability and cash framework.

What the update means for investors

DSM-Firmenich stock traded at 111.10 euros on Lang & Schwarz at 10:13 CET on Friday, November 6, 2026. The quote provides a current market indication as investors weigh the stronger outlook against execution risks in a volatile operating environment.

The company completed its share repurchase program on September 30, buying 7,169,147 shares at an average price of 75.32 euros for total consideration of 540 million euros. Shares bought for capital reduction are expected to be cancelled by the end of the first quarter of 2027, which would reduce issued shares by approximately 2.6%.

Investors can follow the real-time quote of DSM-Firmenich stock for the latest market indication.

Broader market sentiment remains an important backdrop for European equities; see Current market reports.

Further results are due with dsm-firmenich's full-year 2026 publication on February 18, 2027. More news and analyses on DSM-Firmenich stock.